Task: Answer the following question about the molecule with SMILES C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1.
Request: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Result: Phase 1 Clinical Trials
Task: Answer the following question about the molecule with {SMILES__description} {SMILES#}.
{#Description|Question|Request!}: {quest#}
{#Result|Answer|Completion!}: {answ#}
C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1
3-[4-[3-[(2R)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1H-pyridazin-6-one
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.